X4 Pharmaceuticals, Inc.

XFOR · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.4%

Institutions100.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$35.11M	$2.56M	–	$0	$0	$3.00M	–	$3.50M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$5.76M	$797000	–	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$86.88M	-$36.40M	-$107.52M	-$87.57M	-$85.11M	-$59.87M	-$51.70M	-$45.88M
Operating income as a percentage of revenue.	-247.4%	-1423.6%	–	–	–	-1995.8%	–	-1311.0%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$79.20M	-$37.45M	-$101.17M	-$93.87M	-$88.70M	-$62.13M	-$52.81M	-$43.02M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.87	$-0.19	$-0.57	$-1.52	$-3.99	$-3.09	$-4.63	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	$-0.19	$-0.57	$-1.52	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$217.05M	$55.70M	$99.22M	$121.72M	$81.79M	$78.71M	$126.18M	$30.75M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$290.46M	$146.45M	$147.26M	$155.59M	$117.18M	$122.87M	$160.70M	$36.00M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$0	$1.31M	$795000	–	$0	–
Everything the company owes — debt, unpaid bills, and other obligations.	$104.17M	$124.30M	$96.16M	$81.53M	$52.76M	$50.07M	$31.48M	$14.40M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$186.29M	$22.15M	$51.10M	$74.05M	$64.41M	$72.80M	$129.22M	$21.60M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$85.60M	-$130.90M	-$96.50M	-$77.10M	-$70.91M	-$58.82M	-$48.05M	–
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$0	$326000	$60000	$103000	$615000	$1.36M	$174000	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$85.60M	-$131.23M	-$96.56M	-$77.20M	-$71.52M	-$60.18M	-$48.23M	–

	You	Peer avg
P/E	2.8	–
Revenue Growth	+346.3%	-73.8%
ROE	-113.1%	-1661.9%

X4 Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison